



ABN 53 075 582 740

ASX ANNOUNCEMENT
02 December 2021

NEW CONSTITUTION

Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (**Bionomics** or **Company**), a clinical-stage biopharmaceutical company, provides the market with a copy of its Constitution as approved by shareholders at its Annual General Meeting held on Thursday, 2 December 2021.

The Constitution is provided in accordance with ASX Listing Rule 15.4.2.

Released on authority of the Company Secretary.

FOR FURTHER INFORMATION PLEASE CONTACT:

General:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400

CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder ("SAD") and chronic treatment of Post-Traumatic Stress Disorder ("PTSD"). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au